Liu, Chengfei; Zhu, Yezi; Lou, Wei; Nadiminty, Nagalakshmi; Chen, Xinbin; Zhou, Qinghua; Shi, Xu B; deVere White, Ralph W; Gao, Allen C
description
Docetaxel is the first line treatment for castration resistant prostate cancer (CRPC). However, docetaxel resistance rapidly develops. Identifying the critical mechanisms giving rise to docetaxel resistance is the major challenge in advanced prostate cancer.